At this time, Jalyn (dutasteride/tamsulosin) is available as a brand-name drug only, despite the fact that its first patent has expired. It's possible that a generic version could be introduced as soon as November 2015, when the next patent is set to expire, barring any lawsuits or other patents for specific uses of the drug.
Jalyn is jointly manufactured by Catalent Pharma Solutions and Rottendorf Pharma. It is distributed by GlaxoSmithKline. Currently, this medication is protected from generic competition by patents that have not yet expired.
When Will a Generic Version Be Available?
The first patent for Jalyn expired in September 2013. Yet, no generic versions are available. This suggests that another patent, set to expire in November 2015, is still providing protection against generic competition. This is the earliest predictable date that a generic version could become available.
However, there are other circumstances that could come up to extend or shorten this exclusivity period. This could include such things as lawsuits or other patents for specific Jalyn uses. Once the drug goes off-patent, there may be several companies that manufacture a generic Jalyn drug.
Are Dutasteride and Tamsulosin the Same as Generic Jalyn?
No -- dutasteride and tamsulosin are the active ingredients in Jalyn, but they are not a generic version of it. What can be confusing is that the active ingredient of a drug is often referred to as the "generic name."
The generic name is different from a generic version of a medicine. In order for there to be a generic version of a medicine, the original medicine must have gone off-patent, and another company besides the original manufacturer must make the product.
Written by/reviewed by: Kristi Monson, PharmD;Arthur Schoenstadt, MD
Last reviewed by: KristiMonson, PharmD;
List of references (click here):
Jalyn [package insert]. Research Triangle Park, NC: GlaxoSmithKline;2011 June.
Food and Drug Administration, Center for Drug Evaluation and Research. Electronic orange book: approved drug products with therapeutic equivalence evaluations. FDA Web site. Available at: http://www.fda.gov/cder/ob/. Accessed December 3, 2013.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind.
Site users seeking medical advice about their specific situation should consult with their own physician. Click